Guselkumab Immunogenetics (TIG)

Immunogenetic Profiling of Guselkumab for the Treatment of Plaque and Guttate Psoriasis

This is a two-arm open-label study to evaluate the clinical and immunogenetic responses of patients with plaque or guttate psoriasis to treatment with guselkumab.

Study Overview

• Status: Active, not recruiting
• Conditions: Plaque Psoriasis; Psoriasis Guttate
• Intervention / Treatment: Drug: Guselkumab

Detailed Description

Guselkumab (Tremfya®), an IL-23 inhibitor approved for the treatment of moderate-to-severe plaque psoriasis. Given the potential role of IL-23 in the pathogenesis of guttate psoriasis, guselkumab may be an effective option to treat the initial manifestation of guttate psoriasis. This is a two-arm open-label study to evaluate the clinical and immunogenetic responses of patients with plaque or guttate psoriasis to treatment with guselkumab. The primary objective of this study is to assess how treatment with guselkumab changes the immune milieu of the skin in patients with plaque or guttate psoriasis. The secondary objectives of this study are to assess how treatment with guselkumab affects the quality of life and extent of skin disease in patients with plaque or guttate psoriasis.

• Study Type: Interventional
• Enrollment (Estimated): 25
• Phase: Phase 4

Contacts and Locations

Study Locations

• United States
  • California
    • San Francisco, California, United States, 94118
      • UCSF Psoriasis and Skin Treatment Center

Participation Criteria

Eligibility Criteria

• Ages Eligible for Study: 14 years and older (Adult, Older Adult)
• Accepts Healthy Volunteers: Yes

Description

Inclusion Criteria:

For subjects with guttate psoriasis:

• Ability to provide written informed consent and comply with the protocol.
• At least 18 years of age.
• Diagnosis of guttate psoriasis.
• Onset of guttate psoriasis within 12 months.
• Body surface area (BSA) involvement greater than or equal to 5%.
• PASI greater than or equal to 4.
• Subject is considered a candidate for phototherapy or systemic therapy.
• Subject is unlikely to conceive due to male, post-menopausal, or using adequate contraceptive (barrier, hormonal, implant, or permanent sterilization methods). Women of childbearing potential will be allowed to enroll provided they practice adequate forms of birth control.
• Physical exam with no evidence of active skin infection and/or other findings that indicate chronic disease or concomitant inflammatory/immune-mediated skin disease other than psoriasis.

For subjects with chronic plaque psoriasis (control):

• Ability to provide written informed consent and comply with the protocol.
• At least 18 years of age.
• Diagnosis of plaque psoriasis.
• Duration of plaque psoriasis >5 years.
• Body surface area (BSA) involvement greater than or equal to 5%.
• Subject is considered a candidate for phototherapy or systemic therapy.
• Subject is unlikely to conceive due to male, post-menopausal, or using adequate contraceptive (barrier, hormonal, implant, or permanent sterilization methods). Women of childbearing potential will be allowed to enroll provided they practice adequate forms of birth control.
• Physical exam with no evidence of active skin infection and/or other findings that indicate chronic disease or concomitant inflammatory/immune-mediated skin disease other than psoriasis.

Exclusion Criteria:

For subjects with guttate psoriasis:

• Subject is unable to provide written informed consent or comply with the protocol.
• Subject is younger than 18 years of age or older than 70 years.
• Have a history of active, chronic or recurrent infectious disease including HIV, hepatitis B, or hepatitis C.
• Have active tuberculosis or latent tuberculosis without at least 4 weeks of treatment with isoniazid.
• Have current signs or symptoms of severe, progressive, or uncontrolled medical disease.
• Known allergies, hypersensitivity, or intolerance to guselkumab (TremfyaTM) excipients.
• Have a known history of lymphoproliferative disease, including lymphoma, or signs and symptoms suggestive of possible lymphoproliferative disease, such as lymphadenopathy and/or splenomegaly.
• Have any known malignancy or have a history of malignancy (with the exception of basal cell carcinoma, squamous cell carcinoma in situ of the skin, or cervical carcinoma in situ that has been treated with no evidence of recurrence, or squamous cell carcinoma of the skin that has been treated with no evidence of recurrence within 5 years prior to screening)
• Are pregnant, nursing, or planning a pregnancy while enrolled in the study or for 12 weeks after the study agent injection for women or are planning to father a child while enrolled in the study or for 12 weeks after the last study agent injection.
• Are participating in another study using an investigational agent or procedure during participation in this study.
• Have any condition that, in the opinion of the investigator, would compromise the well-being of the subject or the study or prevent the subject from meeting or performing study requirements.
• Subjects possess other diagnoses that, in the investigator's opinion interfere with the evaluation of the subject's guttate psoriasis.
• Pre-existing psoriasis of any type for longer than 6 months. (i.e. plaque, guttate, palmoplantar, pustular, erythrodermic)
• Previous treatment for psoriasis with phototherapy (narrowband ultraviolet (UV) B, broadband UVB, or UVA), systemic agents (methotrexate, acitretin, cyclosporine, apremilast), or biologic agents (etanercept, adalimumab, ustekinumab, secukinumab, etc.)

For subjects with chronic plaque psoriasis:

• Subject is unable to provide written informed consent or comply with the protocol.
• Subject is younger than 18 years of age or older than 70 years.
• Have a history of active, chronic or recurrent infectious disease, including HIV, hepatitis B, or hepatitis C.
• Have active tuberculosis or latent tuberculosis without at least 4 weeks of treatment with isoniazid.
• Have current signs or symptoms of severe, progressive, or uncontrolled medical disease.
• Known allergies, hypersensitivity, or intolerance to guselkumab (TremfyaTM) excipients.
• Have a known history of lymphoproliferative disease, including lymphoma, or signs and symptoms suggestive of possible lymphoproliferative disease, such as lymphadenopathy and/or splenomegaly.
• Have any known malignancy or have a history of malignancy (with the exception of basal cell carcinoma, squamous cell carcinoma in situ of the skin, or cervical carcinoma in situ that has been treated with no evidence of recurrence, or squamous cell carcinoma of the skin that has been treated with no evidence of recurrence within 5 years prior to screening)
• Are pregnant, nursing, or planning a pregnancy while enrolled in the study or for 12 weeks after the study agent injection for women or are planning to father a child while enrolled in the study or for 12 weeks after the last study agent injection.
• Are participating in another study using an investigational agent or procedure during participation in this study.
• Have any condition that, in the opinion of the investigator, would compromise the well-being of the subject or the study or prevent the subject from meeting or performing study requirements.
• Subjects possess other diagnoses that, in the investigator's opinion, interfere with the evaluation of the subject's plaque psoriasis.
• Prior history of guttate psoriasis.

Study Plan

How is the study designed?

Design Details

• Primary Purpose: Treatment
• Allocation: Non-Randomized
• Interventional Model: Parallel Assignment
• Masking: None (Open Label)

Number of Arms

2

Arms and Interventions

Participant Group / Arm	Intervention / Treatment
Experimental: New-onset guttate psoriasis; Subjects will initially be treated with guselkumab 100 mg SQ at weeks 0, 4, and then every 8 weeks thereafter until week 44. At week 44, patients who have not achieved PASI 50 (nonresponders) will be removed from the trial. Patients who achieve between PASI 50 and PASI 75 (partial responders) will continue on drug throughout the remainder of the study. Patients who achieve PASI 75 or greater at week 44 (responders) will have their guselkumab therapy withdrawn and re-treated upon relapse.	Drug: Guselkumab; All subjects will initially be treated with guselkumab 100 mg SQ at weeks 0, 4, and then every 8 weeks thereafter until week 44
Experimental: Chronic plaque psoriasis; Subjects will initially be treated with guselkumab 100 mg SQ at weeks 0, 4, and then every 8 weeks thereafter until week 44. At week 44, patients who have not achieved PASI 50 (nonresponders) will be removed from the trial. Patients who achieve between PASI 50 and PASI 75 (partial responders) will continue on drug throughout the remainder of the study. Patients who achieve PASI 75 or greater at week 44 (responders) will have their guselkumab therapy withdrawn and re-treated upon relapse.	Drug: Guselkumab; All subjects will initially be treated with guselkumab 100 mg SQ at weeks 0, 4, and then every 8 weeks thereafter until week 44

What is the study measuring?

Primary Outcome Measures

Outcome Measure	Measure Description	Time Frame
Lesional CD4+ T effector cells	Mean change from baseline in percent of lesional CD4+ T effector cells producing IL-17	baseline and week 44
Lesional CD8+ T effector cells	Mean change from baseline in percent of lesional CD8+ T effector cells producing IL-17	baseline and week 44

Collaborators and Investigators

• Sponsor: University of California, San Francisco
• Collaborators: Janssen Biotech, Inc.
• Investigators: Principal Investigator: Wilson Liao, MD, University of California, San Francisco

Study record dates

Study Major Dates

• Study Start (Actual): March 1, 2021
• Primary Completion (Actual): April 4, 2025
• Study Completion (Estimated): April 15, 2026

Study Registration Dates

• First Submitted: November 20, 2020
• First Submitted That Met QC Criteria: November 20, 2020
• First Posted (Actual): November 27, 2020

Study Record Updates

• Last Update Posted (Actual): March 30, 2026
• Last Update Submitted That Met QC Criteria: March 24, 2026
• Last Verified: March 1, 2026

More Information

Terms related to this study

• Additional Relevant MeSH Terms: Skin Diseases, Papulosquamous; Skin Diseases; Psoriasis; Skin and Connective Tissue Diseases; Guttate Psoriasis; guselkumab
• Other Study ID Numbers: 20-32273

Plan for Individual participant data (IPD)

• Plan to Share Individual Participant Data (IPD)?: YES
• IPD Plan Description: Non-identifying clinical and research data may be shared with Janssen Biotech, UCSF and FDA, as well as other qualified scientists upon publication and upon request

Drug and device information, study documents

• Studies a U.S. FDA-regulated drug product: Yes
• Studies a U.S. FDA-regulated device product: No